# Doxorubicin vs. Trabectedin Plus Doxorubicin in Non Operable and/or Metastatic STS

> **NCT01104298** · PHASE2 · TERMINATED · sponsor: **Grupo Espanol de Investigacion en Sarcomas** · enrollment: 115 (actual)

## Conditions studied

- Sarcoma

## Interventions

- **DRUG:** Doxorubicin
- **DRUG:** Trabectedin

## Key facts

- **NCT ID:** NCT01104298
- **Lead sponsor:** Grupo Espanol de Investigacion en Sarcomas
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-11
- **Primary completion:** 2012-12
- **Final completion:** 2014-05
- **Target enrollment:** 115 (ACTUAL)
- **Why stopped:** Interim analysis did not show good results for main objective
- **Last updated:** 2015-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01104298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01104298, "Doxorubicin vs. Trabectedin Plus Doxorubicin in Non Operable and/or Metastatic STS". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01104298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*